Early-stage ductal carcinomas generally exhibit high ERα and low ERβ expression, profiles compatible with ERα antagonist or ERβ agonist therapies, whereas high-grade ductal carcinomas often lack ER expression. Here, ESR2 is linked to breast ductal adenocarcinoma.